CBN has become closely associated with nighttime gummies, sleep formulations and aged cannabis. But its reputation as a powerful sedative long predates modern clinical trials investigating its effects on sleep. Does the science live up to the marketing?
What Is CBN?
Cannabinol (CBN) is an oxidative by-product of THC. It forms as THC breaks down through exposure to oxygen, heat, light and time, which explains why aged cannabis contains more CBN and less THC.
First isolated by Cambridge chemists in the 1890s, CBN was the first cannabinoid ever isolated.
CBN has considerably weaker activity at the CB1 receptor than THC. However, evidence regarding its psychoactive effects in humans remains mixed.
The Origins of Its Sleepy Reputation
The popular belief that aged cannabis causes sleepiness because THC converts into CBN has never been conclusively demonstrated.
In 1975, researchers tested CBN and THC in five male volunteers. 50 mg of CBN alone produced no reported feelings of drowsiness, dizziness, drunkenness or being drugged. 25 mg of THC produced those sensations. Combining CBN and THC slightly enhanced feelings of drowsiness and being drugged compared with THC alone.
In 2021, a scientific review screened 99 human studies and concluded that published evidence was insufficient to support claims that CBN promotes sleep.

What Modern Human Trials Reveal
Three placebo-controlled clinical trials published between 2024 and 2026 have provided a clearer picture.
Bonn-Miller et al. (2024): A seven-night study analyzing data from 293 adults found that 20 mg of CBN showed improvements in two secondary outcomes: nighttime awakenings and overall sleep disturbance. However, the primary outcome of overall sleep quality did not improve significantly.
Participants did not fall asleep faster or experience reduced daytime fatigue. Adding CBD provided no additional benefit. The research team included employees of Canopy Growth and Wana Brands.
Kolobaric et al. (2024): A larger trial involving 1,020 adults compared 25 mg, 50 mg and 100 mg of CBN against placebo and 4 mg of melatonin.
All three CBN doses showed improvements in self-reported sleep compared with placebo, but none significantly outperformed melatonin. A later review cautioned that the findings were sensitive to multiple statistical comparisons.
The study was conducted by Radicle Science under contract with Floraworks, the manufacturer of the CBN ingredient tested.
Lavender et al. (2026): The first sleep-laboratory trial — a single-dose crossover study — examined 20 adults diagnosed with insomnia.
Neither 30 mg nor 300 mg of CBN significantly improved the primary outcome of time spent awake after initially falling asleep.
The 300 mg dose improved several secondary outcomes, including time taken to fall asleep, subjective sleep quality and certain measures of sleep architecture. The 30 mg dose did not produce the same improvements in sleep onset or subjective sleep quality observed at 300 mg.
Researchers recorded 247 mild-to-moderate adverse events across all treatment arms, including placebo. No serious adverse events were reported.
Does Combining CBN With CBD Help?
A 2024 study involving 1,793 adults compared six sleep formulations over four weeks.
Adding 15 mg of CBN to 15 mg of CBD produced no significant additional benefit compared with CBD alone.
None of the formulations outperformed 5 mg of melatonin. The trial did not include a placebo-only group.
Animal Research Offers a Possible Explanation
A study published online in November 2024 found that CBN increased both REM and non-REM sleep in rats, following an initial period of sleep suppression.
Its effect on non-REM sleep was comparable in magnitude to zolpidem within the animal experiment. However, partial tolerance developed with repeated dosing.
Researchers also identified an active metabolite, 11-hydroxy-CBN, which demonstrated CB1 receptor activity comparable to THC in a laboratory assay.
The metabolite may contribute to CBN's sleep-related effects, but this mechanism has not been established in humans.
These preclinical findings do not establish equivalent effects in humans.
Is CBN Actually an Effective Sleep Aid?
A November 2026 scientific review concluded that clinical evidence remains inconsistent and that no optimal CBN dosage has been established.
The review also raised concerns about next-day alertness and simulated driving performance following a 300 mg dose.
Human trials have reported preliminary improvements in nighttime awakenings, sleep disturbance and sleep onset, but the findings remain inconsistent. CBN's effectiveness as a sleep aid has not been established.
No CBN product is currently FDA-approved for sleep or any other medical indication.
CBN is a promising area of sleep research, but its reputation as a proven natural sedative remains ahead of the science.
Read next
Parkinson's Disease and Cannabis: What the Clinical Trials Actually Showarticles · Nov 16, 2026
Cannabis & Dreams: Why Do Some Frequent Users Remember Fewer Dreams?articles · Nov 9, 2026
Can Cannabis Help Alzheimer's Disease? Human Trials Show a Narrow Signal for Agitation, Not Memoryarticles · Nov 18, 2026
Sources
- Pita D et al. "Cannabinol for Sleep and Insomnia: A Critical Narrative Review and an Olive-Derived Polyphenol Combination Hypothesis." Nutrients, 2026. PMID: 43030286. — The 2026 verdict review: primary outcomes not consistently positive, no optimal dose.
- Bonn-Miller MO et al. "A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality." Experimental and Clinical Psychopharmacology, 2024. PMID: 37796540. — 293 adults, 20 mg, 7 nights; fewer awakenings, primary outcome missed.
- Kolobaric A et al. "A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Effectiveness and Safety of Melatonin and Three Formulations of Floraworks Proprietary TruCBN for Improving Sleep." Pharmaceuticals, 2024. PMID: 39204082. — 1,020 adults; CBN matched melatonin, industry-funded.
- Lavender IG et al. "Cannabinol for Acute Treatment of Insomnia Disorder in a Randomized Placebo-Controlled Crossover Trial." Journal of Sleep Research, 2026. PMID: 41698831. — First sleep-lab trial; primary outcome missed at both doses.
- Saleska JL et al. "The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep." Journal of the American Nutrition Association, 2024. PMID: 37162192. — 1,793 adults; adding CBN to CBD added nothing.
- Arnold JC et al. "A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats." Neuropsychopharmacology, 2025. PMID: 39528623. — Rat sleep study; the active-metabolite finding.
- Corroon J. "Cannabinol and Sleep: Separating Fact from Fiction." Cannabis and Cannabinoid Research, 2021. PMID: 34468204. — The 2021 review that found no adequate evidence behind the sleep claims.
- Karniol IG et al. "Effects of delta9-tetrahydrocannabinol and cannabinol in man." Pharmacology, 1975. PMID: 1221432. — The 1975 classic: CBN alone did not make volunteers drowsy.
0 comments